Table 5.

Characteristics of pre-NCD and post-NCD adopters of coverage for next-generation tumor sequencing.^*

Payer characteristic	Percentage of pre-NCD adopters, n = 17	Percentage of post-NCD adopters, n = 16	P value
Size, in covered lives
1 000 000 or more	41	44	1.0
Less than 1 000 000	59	56
BlueCross BlueShield Member
Yes	29	44	0.5
No	71	56
Offer Medicare Advantage
Yes	65	87.5	0.2
No	35	12.5
Adopted a third-party policy
Yes	53	37.5	0.5
No	47	62.5

Sequencing indicates next-generation tumor sequencing.

^*Adopters are payers who adopted positive coverage for sequencing on or before April 1, 2019, for any indication, any sequencing test(s), and any policy stipulation (eg, with or without prior authorization). Pre-NCD adopters are payers who adopted positive coverage for sequencing before the Centers for Medicare and Medicaid Services (CMS) released draft National Coverage Determination (NCD) on November 30, 2017. Post-NCD adopters are payers who adopted positive coverage for sequencing after CMS released the draft NCD. Size is reported for lives covered by commercial insurance. Offer Medicare Advantage includes payers who service Medicare Advantage plans on behalf of Medicare. Third-party policy is provided by third-party laboratory benefit management company.